IQSTAX education library
Clear summaries, evidence limits and primary sources. Browse medicines, research compounds, vitamins and minerals.
U.S. information · sources reviewed October 17, 2026
Listing an item does not recommend it or establish its safety. Research-only products are not approved medicines. Approval applies to a specific product and use, not every material with the same ingredient name.
These brief summaries are not complete medicine guides. Use the linked sources and your clinician or pharmacist for personal questions. No dosing, mixing or treatment instructions are provided.
48 entries · select a name to read more
Prescription medicine · product-specific approval
Phentermine, an appetite suppressant approved for short-term use.
Cardiovascular conditions and other medicines affect suitability.
Research compound · no approved U.S. medicine identified in cited review
An experimental growth-hormone-fragment analog, not an approved obesity treatment.
FDA found insufficient effectiveness evidence for obesity and inadequate safety information for proposed routes. Food-ingredient claims do not establish injectable-drug approval.
Prescription medicine · product-specific approval
A prescription appetite suppressant used for short-term weight management.
Suitability depends on health history and other medicines.
Research compound · no approved U.S. medicine identified in cited review
An experimental peptide with predominantly nonclinical evidence and limited human reports.
FDA’s 2026 assessment found insufficient evidence for ulcerative colitis. This does not establish tendon, muscle or joint benefits; safety and product characterization remain uncertain.
Investigational · not FDA-approved
An investigational amylin analog being studied for weight management, including in the REDEFINE 1 clinical program.
FDA states cagrilintide is not an approved drug ingredient. Studies of cagrilintide alone and combination regimens answer different questions.
Investigational combination · not an approved research-vial product
Cagrilintide plus semaglutide has clinical trial evidence from REDEFINE 1. It is distinct from other “Cagri” combinations.
The trial does not validate a research vial, fixed ratio, or combination with tirzepatide or retatrutide. Gastrointestinal adverse events were common in the study.
Research compound · no approved U.S. medicine identified in cited review
An experimental combination of agents affecting growth-hormone signaling.
Component studies do not establish this blend’s benefits or safety. FDA identifies limited clinical evidence and significant safety uncertainties for the components.
Research compound · no approved U.S. medicine identified in cited review
Different forms share the CJC name. Findings from a long-acting form cannot automatically be applied to non-DAC products.
Hormone-level changes do not establish recovery or longevity benefits. FDA identifies limited clinical evidence, naming problems and safety concerns.
Prescription medicine · product-specific approval
Naltrexone and bupropion combined for weight management.
Opioid use, seizure history and blood pressure affect suitability.
Prescription medicine · product-specific approval
A prescription appetite suppressant used for short-term weight management.
Cardiovascular precautions and medicine interactions matter.
Research compound · no approved U.S. medicine identified in cited review
An experimental neuropeptide; its name does not establish a treatment for insomnia.
FDA found the human findings preliminary and inconclusive. Evidence from older studies cannot establish safety or benefit for different formulations or routes.
Research compound · no approved U.S. medicine identified in cited review
An experimental tetrapeptide. Studies of biomarkers do not establish longer life or clinical sleep benefits.
FDA’s 2026 assessment found insufficient evidence for insomnia and inadequate safety information. Epitalon and epithalamin are not interchangeable.
Prescription medicine · product-specific approval
Oral GLP-1 medicine approved for weight management in eligible adults.
Approval applies to the prescribed product; it does not extend to research-labeled material.
Prescription medicine · product-specific approval
Teduglutide is a GLP-2 analog for short bowel syndrome in people needing IV nutrition or fluids.
GLP-2 is a separate pathway from GLP-1. Gattex is not a weight-loss medicine.
Research compound · no approved U.S. medicine identified in cited review
A copper-binding peptide with research that varies by route and formulation. Cosmetic availability is not injectable-drug approval.
FDA notes limited human safety information and potential immune reactions for injectable GHK-Cu. Topical or animal findings cannot establish injectable benefits.
Research compound · no approved U.S. medicine identified in cited review
An experimental growth-hormone-releasing peptide.
FDA notes limited safety data, possible immune reactions, cortisol effects and increased blood glucose.
Research compound · no approved U.S. medicine identified in cited review
GLOW is a nonstandard name used for GHK-Cu, BPC-157 and TB-500; the two-component BPC-157 + TB-500 blend is different.
No direct clinical evidence for these exact named formulations was identified in the reviewed sources. Combining ingredients does not establish synergy, consistent identity or safety.
Prescription medicine · product-specific approval
Setmelanotide for certain rare genetic causes of obesity.
It is not a general weight-loss medicine.
Research compound · no approved U.S. medicine identified in cited review
An experimental growth-hormone secretagogue with route-specific evidence.
FDA reports serious adverse events in an intravenous study and insufficient safety information for certain other injectable routes. This does not establish causation or quantify another route’s risk.
Research compound · no approved U.S. medicine identified in cited review
A nonstandard blend name used for KPV, BPC-157, GHK-Cu and TB-500. The name does not establish amounts or product identity.
No clinical evidence for this exact named blend was identified in the reviewed sources. Evidence for a component does not establish the combination’s safety, effectiveness or stability.
Research compound · no approved U.S. medicine identified in cited review
An experimental three-amino-acid peptide studied in cells and animals.
FDA’s 2026 assessment found no human administration data for the evaluated forms. Laboratory findings do not establish treatment of human bowel, skin or wound conditions.
Prescription medicine · product-specific approval
A phentermine product for short-term weight management.
Product strengths and instructions differ.
Nutrient · formulation matters
A mineral involved in muscle, nerve and metabolic functions.
Supplements can interact with medicines and cause digestive side effects.
Prescription medicine
Helps control blood glucose in type 2 diabetes.
Kidney function and other health conditions affect suitability.
Research compound · no approved U.S. medicine identified in cited review
A mitochondrial-derived peptide investigated mainly in nonclinical treatment research.
Measuring naturally occurring MOTS-c in people is not a treatment trial. FDA’s 2026 assessment found no human administration data for the evaluated forms; weight-loss and longevity benefits remain unestablished.
Prescription medicine · product-specific approval
Tirzepatide used for type 2 diabetes; it acts on GIP and GLP-1 receptors.
Zepbound is a separate product for weight management.
Evidence and product quality vary
A naturally occurring coenzyme; its role in cells does not establish benefits from wellness infusions.
FDA has reported adverse events after injectable NAD+ and cautions against ingredients unsuitable for sterile compounding.
Prescription medicine · product-specific approval
Injectable semaglutide used for type 2 diabetes.
Wegovy and Ozempic have different approved uses and product instructions.
Prescription medicine · product-specific approval
A prescription appetite suppressant used for short-term weight management.
Use is limited by product-specific precautions and clinical assessment.
Prescription medicine · product-specific approval
Phentermine and topiramate combined for weight management.
Pregnancy carries a risk of birth defects; the product has specific safety precautions.
Investigational · not FDA-approved
An investigational triple-receptor agonist studied in Phase 3 trials for obesity and related conditions.
FDA states retatrutide is not an approved drug ingredient. Trial findings do not validate research-labeled products. “GLP-3” is an informal nickname, not a scientific drug class.
Prescription medicine · product-specific approval
Oral semaglutide used for type 2 diabetes.
Oral and injectable semaglutide formulations are not interchangeable dose for dose.
Prescription medicine · product-specific approval
Liraglutide for long-term weight management.
Victoza is a separate liraglutide product for type 2 diabetes.
Research compound · no approved U.S. medicine identified in cited review
An experimental neuroactive peptide with limited human clinical reports.
FDA’s 2026 assessment found insufficient evidence for the evaluated neurological uses. These findings do not establish cognitive enhancement in healthy people.
Research compound · no approved U.S. medicine identified in cited review
A name used for a thymosin-beta-4-related fragment; it is not interchangeable with full-length thymosin beta-4.
FDA’s 2026 assessment did not identify human clinical studies of the evaluated substances. Identity, human safety and healing benefits remain unestablished.
Specific EGRIFTA products are FDA-approved
Prescription tesamorelin reduces excess abdominal fat in adults with HIV-associated lipodystrophy; it is not approved for general weight loss.
Approval does not extend to research material. Formulations are not automatically substitutable, and the label includes glucose, IGF-1, fluid-retention and malignancy precautions.
Prescription medicine · product-specific approval
An injectable testosterone formulation for certain causes of testosterone deficiency.
Clinical assessment and ongoing monitoring are necessary.
Prescription medicine · product-specific approval
An injectable testosterone formulation for certain causes of testosterone deficiency.
Route and precautions depend on the specific prescribed product.
Prescription medicine · product-specific approval
Topical testosterone for certain causes of testosterone deficiency.
Product precautions address accidental transfer to other people.
Prescription medicine · product-specific approval
A long-acting testosterone formulation for certain causes of testosterone deficiency.
Aveed requires healthcare administration and observation because of serious reaction risks.
Prescription medicine · product-specific approval
Dulaglutide is a GLP-1 medicine for type 2 diabetes.
It is distinct from GLP-1 products approved for weight management.
Prescription medicine · product-specific approval
Liraglutide used for type 2 diabetes.
Saxenda is a separate liraglutide product for weight management.
Nutrient · formulation matters
Supports nerve function and healthy blood cells.
Treating deficiency is different from increasing energy in people who already have sufficient B12.
Nutrient · formulation matters
Supports calcium absorption and bone health.
Excess supplementation can be harmful; needs vary with age and health.
Prescription medicine · product-specific approval
Injectable semaglutide for weight management in eligible patients.
The injection and tablet products have different instructions and are not interchangeable dose for dose.
Prescription medicine · product-specific approval
Oral semaglutide for weight management in eligible patients.
Tablet and injection formulations have different instructions; the brand name alone does not identify the formulation.
Prescription medicine · product-specific approval
Orlistat reduces absorption of dietary fat.
Digestive effects and reduced absorption of some vitamins can occur.
Prescription medicine · product-specific approval
Tirzepatide for weight management. It acts on GIP and GLP-1 receptors.
Mounjaro is a separate tirzepatide product with different approved uses.
Try another name or choose All categories.
Track. Stax. Progress.
Keep your items, schedules and history together.
See pricing and trial terms